|
|
|
|
|
|
|
|
|
|
|
10.03.26 - 14:30
|
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA (GlobeNewswire EN)
|
|
|
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has lifted the previously issued Complete Response Letter and resumed review of its Biologics License Application (“BLA”) seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy (“DMD”) cardiomyopathy. The submission has been classified as a Class 2 resubmission, with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 22, 2026....
|
|
|
|
|
24.02.26 - 15:06
|
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference (GlobeNewswire EN)
|
|
|
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that results from its Phase 3 HOPE-3 clinical study of Deramiocel in Duchenne muscular dystrophy (DMD) have been selected for a late-breaking oral presentation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, taking place March 8–11, 2026, in Orlando, Florida....
|
|
|
|
|
|
|
|
|
|
|
05.12.25 - 12:18
|
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions....
|
|
|
|
|
04.12.25 - 22:03
|
Capricor Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering....
|
|
|
03.12.25 - 18:30
|
Capricor +535%: Biotech-Tipp schlägt heftig ein! (Sharedeals)
|
|
|
Capricor Therapeutics macht heute nicht nur mit positiven Studiennews auf sich aufmerksam: Mit einem gigantischen Kursfeuerwerk macht mein Biotech-Tipp aus dem Juli alle seine Aktionäre glückselig. Was steckt dahinter? Capricor Therapeutics hat in der Entwicklung seiner Zelltherapie Deramiocel gegen Duchenne-Muskeldystrophie einen wichtigen Meilenstein erreicht. In der Phase-3-Studie HOPE-3 wurde der primäre Endpunkt erfolgreich erfüllt. Ich […]
The post Capricor +535%: Biotech-Tipp schlägt heftig ein! first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
